





































Neurofbromatosis Type 1 Implicates Ras Pathways in the Genetic 
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Abstract 
The genetic architecture of neurodevelopmental disorders is largely polygenic, non-specifc, and pleiotropic. This complex
genetic architecture makes the search for specifc etiological mechanisms that contribute to neurodevelopmental risk more
challenging. Monogenic disorders provide an opportunity to focus in on how well-articulated signaling pathways contribute
to risk for neurodevelopmental outcomes. This paper will focus on neurofbromatosis type 1 (NF1), a rare monogenic disorder
that is associated with varied neurodevelopmental outcomes. Specifcally, this paper will provide a brief overview of NF1
and its phenotypic associations with autism spectrum disorder, attention-defcit/hyperactivity disorder, and specifc learn-
ing disorders, describe how variation within the NF1 gene increases risk for neurodevelopmental disorders via altered Ras
signaling, and provide future directions for NF1 research to help elucidate the genetic architecture of neurodevelopmental
disorders in the general population. 
Keywords Genetic architecture · Neurodevelopmental disorders · Neurofbromatosis type 1 
Elucidating the genetic architecture of neurodevelopmental
disorders is essential to try to understand the neurobiology
underlying such phenotypes. The term ‘genetic architecture’
refers to the characteristics of genetic variation that infu-
ence phenotypic heritability (Mackay 2001; Timpson et al.
2018). In particular, it includes the number of genetic vari-
ants contributing to a given phenotype, the strength of their
efects on a given phenotype, the frequency of those genetic
variants in the population, and how they interact with one
another and the environment (Gratten et al. 2014; Timp-
son et al. 2018). In contrast to heritability alone, genetic
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architecture refers to our broad understanding of all genetic
factors and their mechanisms that infuence a given pheno-
type (Timpson et al. 2018). 
Fully articulating the genetic architecture of neurodevel-
opmental disorders has been challenging due to their largely
polygenic, non-specifc, and pleiotropic nature (Boyle et al.
2017; O’Donovan and Owen 2016; Watanabe et al. 2019). 
Large-scale twin and molecular genetic studies of neurode-
velopmental disorders increasingly investigate the shared
genetic underpinnings across disorders (Brain Consortium
et al. 2018; Posthuma and Polderman 2013). For example,
there is a considerable genetic overlap between autism spec-
trum disorder (ASD) and attention-defcit/hyperactivity dis-
order (ADHD), with genetic correlations ranging from 0.22
to 0.88 (Grove et al. 2019; Ghirardi et al. 2018; Lundström
et al. 2011; Ronald et al. 2008, 2010, 2014). Genetic risk for 
ASD and ADHD is also shared with reading problems (Ced-
erlöf et al. 2017; Verhoef et al. 2019), educational attainment
(Demontis et al. 2019; Grove et al. 2019) and intellectual
disability, among other outcomes (Demontis et al. 2019; 
Faraone et al. 2017). The strong genetic correlations indi-
cate that neurodevelopmental disorders likely share common
genetic pathways. 
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Monogenic disorders present a unique opportunity to
enrich our understanding of the genetic architecture of neu-
rodevelopmental disorders in the general population. While
monogenic disorders are biologically complex, they ofer an
opportunity to focus in on the multilevel sequelae of putative
genetic pathways hypothesized to be afected in the disorder,
which often result in varied neurodevelopmental outcomes.
This approach may identify specifc genetic pathways impli-
cated in neurodevelopmental disorders in the general popula-
tion and provide novel targets for intervention. 
Neurofbromatosis type 1 (NF1) is a monogenic disorder
that provides a model to understand how well-articulated
genetic signaling pathways contribute to neurodevelopmen-
tal disorders more broadly (Acosta et al. 2012). The aims of
this review are to: (1) provide a brief overview of NF1 and
the associations between NF1 and ASD, ADHD, and spe-
cifc learning disorders (SLD); (2) outline how pathogenic
variation within the NF1 gene increases risk for neurodevel-
opmental disorders via altered Ras signaling; and (3) provide
future directions for NF1 research to help clarify the genetic 
architectures underlying neurodevelopmental disorders. 
Neurofbromatosis type 1 (NF1) 
NF1 is an autosomal dominant and fully penetrant genetic
condition. It is estimated to afect about 1 in 2700–3000
live births (Evans et al. 2010; Uusitalo et al. 2015) and is
characterized by café-au-lait macules, skinfold freckling,
lisch nodules, neurofibromas, and neurodevelopmental
disorders (National Institutes of Health 1988; Vogel et al.
2017; Williams et al. 2009). It is caused by mutations that
occur in the NF1 gene, at chromosome 17q11.2, which spans
approximately 350 kb and 60 exons. To date, over 3000 dif-
ferent germline mutations within the NF1 gene have been
identifed as pathogenic (Gutmann et al. 2017; Koczkowska
et al. 2018). Approximately half of NF1 cases result from a
spontaneous mutation and the other half of cases are familial
(McKeever et al. 2008; Evans et al. 2010). The phenotypic
expression of NF1 is highly variable making it difcult to
predict prognosis (Rieley et al. 2011; Sites et al. 2019). Sev-
eral mechanisms have been proposed to underlie the variable
phenotypic expression, including allelic variation, epistatic
interactions, second hit events in the NF1 gene, modifying
genes, epigenetic changes, and environmental infuences
(Easton et al. 1993; Rieley et al. 2011; Sites et al. 2019). 
See Gutmann et al. (2017) and Miller et al. (2019) for a
more extensive review of the clinical phenotype in patients
with NF1. 
NF1 and neurodevelopmental disorders 
NF1 is associated with increased risk for neurodevel-
opmental disorders compared to the general population
(Acosta et al. 2006, 2012; Walsh et al. 2013; Torres Nupan
et  al. 2017; Vogel et  al. 2017). This brief review will
focus on the association between NF1 and ASD, ADHD,
and SLD. Neuroimaging fndings in NF1 are outside the
scope of this paper. See Klein et al. (2017) and Payne et al.
(2010) for reviews on this topic. 
NF1 and autism spectrum disorder (ASD) 
The prevalence rates of ASD symptomatology in individu-
als with NF1 range from about 10% to 40% (Eijk et al.
2018; Morris et al. 2016), as compared to 1.7% in the gen-
eral population (Baio et al. 2018). Some studies, but not
all (Garg et al. 2013), indicate that males with NF1 appear
to be at slightly greater risk of developing ASD symptoms
(1.6:1 to 2.68:1 sex ratio); however, this risk is smaller
than the 4:1 sex ratio typically observed in general ASD
samples (Garg et al. 2016; Morris et al. 2016). A recent
study found that individuals with pathogenic NF1 muta-
tions within the 3′ end of the NF1 gene (between exons
34 and 57) had higher quantitative autistic trait severity,
relative to individuals with a mutation in the 5′ end of
the gene (Morris and Gutmann 2018); however, additional
research is needed to explore mechanisms underlying this
association. 
NF1 and attention‑defcit/hyperactivity disorder (ADHD) 
Attention deficits are one of the most commonly reported
concerns in children with NF1. Research indicates that
between 38–67% of NF1 youth meet diagnostic criteria
for ADHD (Hyman et al. 2005; Koth et al. 2000; Lidzba
et al. 2012; Mautner et al. 2002), relative to 5.9% in the
general population (Willcutt 2012). Studies within NF1
samples do not indicate increased rates of ADHD in males
compared to females, as is seen in general ADHD sam-
ples (Acosta et al. 2006; Garg et al. 2013; Hyman et al.
2005; Koth et al. 2000; Lidzba et al. 2012). Additionally,
executive functioning impairments are associated with
ADHD in the general population (Willcutt et al. 2005) 
and are often identified in NF1 (Beaussart et al. 2018; 
Torres Nupan et al. 2017). Some research suggests that
up to 70% of children with NF1 exhibit executive func-
tioning deficits (Hyman et al. 2005; Payne et al. 2011). A
recent meta-analysis found that working memory, plan-












        









         
       
 










flexibility were the most common executive functioning
deficits in NF1, in descending order of severity (Beaus-
sart et al. 2018). 
NF1 and specifc learning disorders (SLD) 
It is estimated that about 20–60% of individuals with NF1
meet criteria for a SLD (Ferner et al. 2007; Hyman et al.
2005), which is significantly higher than SLD rates in
samples of unaffected siblings of individuals with NF1
(8%; Hyman et al. 2005), and in the general population
(5–15%; American Psychiatric Association 2013). In par-
ticular, reading disorders are common in NF1 (Hyman
et al. 2005; Vogel et al. 2017), with the phenotype involv-
ing cognitive processes implicated in dyslexia (Chaix
et al. 2018; Cutting et al. 2000; Cutting and Levine 2010; 
Orraca-Castillo et al. 2014; Watt et al. 2008). Math dis-
orders, or dyscalculia, also occur at a higher frequency
in NF1 compared to the general population (Moore 2009; 
Orraca-Castillo et al. 2014). 
Prioritizing NF1 for neurodevelopmental disorder 
research 
The overlap between NF1 and neurodevelopmental disorders
highlights the potential impact of pathogenic mutations in
the NF1 gene. Rare genetic disorders that achieve genome-
wide association with a neurodevelopmental domain should
be prioritized for research (Sanders et al. 2019). A genome-
wide association threshold has been proposed that is based
on the proportion of individuals with the neurodevelop-
mental disorder and a de novo protein truncating mutation
in the same gene relative to the number of total cases, and
the mutation rate/size of the gene (see Fig. 3 in Sanders
et al. 2019). In the absence of available genome-wide asso-
ciation data, a population attributable risk estimate, which
estimates the proportion of neurodevelopmental disorder
cases due to a risk factor, like NF1, may serve as a prelimi-
nary indicator to prioritize rare genetic disorders for further
study. Based on available estimates, NF1 would likely sur-
pass the threshold for genome-wide signifcant association
with ASD, ADHD, and SLD (see Table 1). Although many
Table 1 Neurodevelopmental disorder population attributable risk due to NF1 
ND Prevalence of ND in 
general population (%) 
Prevalence of ND 
in NF1 (%) 
RR AR PAR (%) Expected number of NF1 cases with de 
novo PTV in 100,000 ND cases 
ASD 1.68a 10.9–39.2b,c 6.49–23.33 9.22–37.52 0.31–1.25 103–420 
ADHD 5.90d 38.3–67.6e,f 6.49–11.46 32.40–61.70 1.08–2.06 363–691 
SLD 9.70g 19.80–61.00e,h 2.04–6.29 10.10–51.30 0.34–1.71 113–575 
RR, AR, and PAR estimates follow Fletcher and Wagner (1996). The crude RR estimate is derived from the prevalence rate of the neurodevel-
opmental disorder within NF1 divided by the prevalence rate of the neurodevelopmental disorder in the general population. AR is the prevalence 
rate of the neurodevelopmental disorder within the NF1 population minus the prevalence rate of the neurodevelopmental disorder in the general 
population. PAR is the attributable risk multiplied by .03̄, which is the estimated prevalence of NF1 in the general population (Uusitalo et al. 
2015). The frequency of de novo NF1 cases, with a protein truncating mutation, within 100,000 neurodevelopmental disorder cases from the 
general population is estimated (Sanders et al. 2019). A crude estimate was derived by multiplying PAR by 100,000, multiplying the product by 
.42 as approximately 42% of NF1 cases are de novo (Evans et al. 2010) and multiplying that product by .8 as approximately 80% of NF1 cases 
have a protein truncating mutation (Upadhyaya and Cooper 1998). The range of RR, AR, and PAR estimates are based on the range of preva-
lence rates of neurodevelopmental disorders within NF1, reported in the literature. Despite the expected increased mutational rate of NF1, due to 
its large size, conservative estimates of the number of NF1 cases with de novo protein truncating variants would reasonably surpass the genome-
wide signifcant association threshold (see Sanders et al. 2019) 
ND neurodevelopmental disorder, PTV protein truncating variant, ASD autism spectrum disorder, ADHD attention-defcit/hyperactivity disorder, 





eHyman et al. (2005) 
fLidzba et al. (2012) 
gAltarac and Saroha (2007) 












        
 
          
 








          




       
 
          
   
rare genetic disorders are associated with increased risk
for neurodevelopmental disorders (Zhu et al. 2014), NF1
demonstrates the qualities of a strong candidate for further
neurodevelopmental disorder research. Further below, we
provide examples of experimental models of NF1 which
have provided the foundation for human clinical trials (see
Cimino and Gutmann 2018 for a broader review of this).
Taken together, NF1 is a very strong candidate to be prior-
itized for further study about mechanisms underlying these
neurodevelopmental disorders. 
Genetic, molecular and cellular mechanisms 
between NF1 and neurodevelopmental 
disorders 
The NF1 gene encodes for neurofbromin, a large 2818
amino acid protein which includes a small 300-residue
domain structurally similar to GTPase-activating proteins
(GAP; Gutmann et al. 2017). Particularly relevant to cogni-
tive and behavioral outcomes in NF1, neurofbromin nega-
tively regulates Ras activity (see Fig. 1; Diggs-Andrews
and Gutmann 2013; Gutmann et al. 2017; Anastasaki and
Gutmann 2014). Heterozygous pathogenic mutations in
the NF1 gene lead to decreased neurofbromin expression,
or a truncated or nonfunctional protein, and increased cell
growth and survival, leading to tumor development and can-
cer susceptibility (Basu et al. 1992; DeClue et al. 1991). NF1
is expressed in a variety of cells, and especially in neurons
and various glial cell types, including oligodendrocytes,
astrocytes, and schwann cells (Daston et al. 1992; DeClue
et al. 1991; Gutmann et al. 2017, 1991). NF1 includes four
alternatively spliced exons, 9a, 10a-2, 23a and 48a (Trovó-
Marqui and Tajara 2006). In particular, NF1 ex9a and NF1
ex23a isoforms are highly expressed in the mouse brain and
are linked to NF1 neurodevelopmental outcomes (Gutmann
et al. 1999; Costa and Silva 2002). While NF1 allelic vari-
ation is linked to NF1 expression levels (Hofmeyer et al.
1995), there is an absence of published NF1 expression data 
in the developing human brain. 
Ras pathways 
Animal and human cellular models of NF1 are utilized to
postulate mechanisms that underlie NF1 neurodevelop-
mental outcomes (see Schwetye and Gutmann 2014 for a
review). This research implicates pathogenic mutations in
NF1 with increased Ras/RAF/MEK/ERK, AKT/mTOR and
AC/cAMP signaling (see Fig. 1), and related alterations in
GABAergic and dopaminergic functioning. 
Fig. 1 Neurofbromin and Ras signaling pathways. Neurofbromin 
negatively regulates Ras activity by inactivating Ras-bound GTP, 
leading to inactive GDP-bound Ras. Activated Ras controls cell 
growth by afecting the RAF/MEK/ERK and Akt/mTOR pathways 
(Gutmann et  al. 2017). Ras also positively regulates cyclic AMP 
(cAMP), via PKCζ activation of G protein-coupled receptors (GPCR) 
and activation of adenylyl cyclase (AC), which controls cell survival 
and neurite length in mammal neuronal cells (Anastasaki and Gut-
mann 2014). Pathogenic mutations within NF1 lead to increased Ras-
ERK, Ras-mTOR, and Ras-cAMP signaling activity and increased 
cell growth and survival, and decreased axonal length. ERK extracel-
lular signal-regulated kinase, mTOR mechanistic target of rapamycin 
 
















































        
 
 























Nf1 ± mice demonstrate enhanced ERK activity and
increased GABA in presynaptic hippocampal neurons, with
defcits in Long Term Potentiation (LTP), hippocampal
plasticity and spatial learning (Costa et al. 2002; Cui et al.
2008). Lovastatin, an inhibitor of farnesyltransferase down-
regulation of Ras activity, decreases Ras-ERK activity in
the rodent brain and improves memory, learning and atten-
tion (Li et al. 2005). Decreasing Ras pharmacologically with
GABA receptor blockers also improves memory, learning,
and attention (Costa et al. 2002; Cui et al. 2008). Addition-
ally, Nf1 ± mice exhibit increased GABA/glutamate ratios
in the prefrontal cortex and striatum as well as increased
GABA (A) receptor density in the hippocampus, which
indicates that diferent mechanisms may lead to GABAe-
rgic inhibition in diferent brain regions (Gonçalves et al.
2017). These fndings have led to the hypothesis that NF1
may provide a model for the excitation/inhibition imbalance 
hypothesis in ASD (Foss-Feig et al. 2017) and ADHD (Kim 
et al. 2017). Here, the imbalance between glutamatergic and 
GABAergic processes, among other afected pathways, may
explain altered neural activity and contribute to the cognitive
and behavioral characteristics of ASD and ADHD. 
RASopathies, or rare disorders caused by mutations in
Ras-ERK pathway, broadly increase risk for neurodevel-
opmental disorders (Adviento et al. 2014; Pantaleoni et al.
2017; Pierpont and Wolford 2016; Vithayathil et al. 2018). 
RASopathies include Cardio-Facio-Cutaneous syndrome,
Costello syndrome, Noonan syndrome and Legius syn-
drome. Further, common single nucleotide polymorphisms
(SNPs) within RASopathy genes, and other SNPs that inter-
act with Ras-ERK pathway genes, were found to be enriched
in a general ASD sample (Mitra et al. 2017). Taken together,
rare and common variation in Ras-ERK pathway genes are
implicated in risk for neurodevelopmental disorders. 
Akt/mTOR pathway 
Decreased neurofbromin and increased Ras activation also
lead to disruptions in the Akt/mTOR pathway (Lee and
Stephenson 2007). The Akt/mTOR pathway regulates the
cell cycle. In NF1, increased activation of the Akt/mTOR
pathway is associated with poor prognosis of malignant
peripheral nerve sheath tumors (Endo et al. 2013). The Akt/ 
mTOR pathway also disrupts the cell cycle in other tissues
and is implicated in megalencephaly and intracranial vol-
ume (Dobyns and Mirzaa 2019; Mirzaa et al. 2016; Rei-
jnders et al. 2017). Indeed, approximately 50% of individuals
with NF1 present with macrocephaly (Van Es et al. 1996), 
which is related to megalencephaly (Cutting et al. 2002; 
Said et al. 1996; Steen et al. 2001). A range of genetic vari-
ants that mildly activate the Akt/mTOR are associated with
megalencephaly, intellectual disability, and ASD (Dobyns
and Mirzaa 2019). Megalencephaly is also associated with
intellectual disability (Reijnders et al. 2017) and ASD in
the general population (Sokol et al. 2019). Transcriptomic
dysregulation in the Akt/mTOR pathway is associated
with ASD and brain/kidney cancers in the general popu-
lation (Forés-Martos et al. 2019). Further, mice defcient
for Cntnap2, a replicated ASD susceptibility gene (Anney
et al. 2012), demonstrate hyperactive Akt/mTOR signaling
in the hippocampus and showed ASD like behaviors (Xing
et al. 2019). Treatment with Akt and mTOR inhibitors led
to improved social behavior in mouse models (Xing et al.
2019). Consistent with fndings in NF1, this demonstrates
that ASD susceptibility genes identifed in general ASD
samples may increase Akt/mTOR signaling. Additionally,
fndings indicate that the Akt/mTOR pathway may alter
neurodevelopmental vulnerability in both NF1 and general
populations and may provide novel therapeutic targets. 
Defcits in cAMP generation 
Drosophila, mouse, and induced pluripotent stem cell (iPSC)
NF1 patient derived neural cell models indicate that neurof-
bromin regulates cyclic AMP (cAMP) through Ras activa-
tion (Anastasaki and Gutmann 2014) and neuropeptide and
G-protein stimulated adenylyl cyclase (AC) activity (Tong
et al. 2002). Nf1 ± mice exhibit decreased cAMP, which
decreases neurite outgrowth and cone growth in hippocam-
pal and retinal cells (Brown et al. 2010; Anastasaki and Gut-
mann 2014). Decreased cAMP concentration in brain tissue
is a hypothesized risk for neurodevelopmental disorders in
NF1 (Tong et al. 2002) and ASD in the general population
(Kelley et al. 2008; Kim et al. 2017; Sethna et al. 2017). 
Increasing cAMP concentration pharmacologically rescues
learning, but not memory problems, within an NF1 zebrafsh
model (Wolman et al. 2014) and memory in a Fragile X
drosophila and mouse model (Choi et al. 2016). 
NF1 molecular and cellular neurodevelopmental mecha-
nisms have also been examined using iPSC NF1 patient
derived neural cell models (Anastasaki et al. 2015; Sagata
et al. 2017). Neural progenitor cells, derived via iPSC
from NF1 cases, demonstrate increased Ras, decreased
cAMP, and a reduction in dopamine levels (Anastasaki
et al. 2015). Transcriptomic analysis indicates increased
expression of genes involved in inhibiting apoptosis in
NF1 males and control males (Sagata et al. 2017). This
sex specifc fnding may also help to explain increased
risk for ASD among NF1 males compared to NF1 females
(Chisholm et al. 2018; Morris et al. 2016). Apoptosis may
be disturbed in early stage neuronal cells within NF1,
which may be one route to megalencephaly (Pirozzi et al.
2018). Finally, diferences in gene expression are rescued
by the administration of forskolin which activates adenylyl
         
 
 
























































cyclase (AC) and raises cAMP levels (Insel and Ostrom
2003) during early development (Sagata et al. 2017). Phar-
macological increases in cAMP may help protect against
ASD for those experiencing risk from this pathway (Sagata
et al. 2017). 
Impaired dopaminergic functioning 
Mutations in the NF1 gene also alter dopaminergic func-
tioning. For example, an Nf1 ± mouse model showed a
reduction in striatal dopamine and selective and non-selec-
tive attention defcits, which normalized with the admin-
istration of methylphenidate or L-DOPA (Brown et al.
2010). Whole brain levels of dopamine, however, are not
reduced in NF1 mouse models (Maloney et al. 2018). In
addition, van der Voet et al. (2016) found that a NF1 dros-
ophila model displayed a hyperactivity phenotype (night-
time locomotion) which was linked to impaired dopamin-
ergic functioning, and was rescued with methylphenidate.
In NF1 patient derived neurons via iPSC, the level of neu-
rofbromin expression is positively associated with dopa-
mine levels within NF1 cases (Anastasaki et al. 2015). 
Taken together, varied neurofbromin expression within
NF1 samples impacts dopaminergic functioning which
may predict risk for neurodevelopmental disorders, such
as ADHD. Low dose methylphenidate improves objective
measures of attention (Mautner et al. 2002) and ADHD
behavioral symptoms in NF1 youth (Lion-François et al.
2014; Morris and Gutmann 2018). Additionally, efects
of stimulant medication on ADHD symptoms within NF1
are comparable to those in the general ADHD population
(Faraone and Buitelaar 2010). Despite similar outcomes
for methylphenidate on NF1-ADHD and within general
ADHD samples at a behavioral level, diferences in brain
functioning, doses, and side efects between NF1-ADHD
and general ADHD samples have not been examined. 
In summary, NF1 is implicated in several well-articulated
Ras pathways (Ras/RAF/MEK/ERK; Akt/mTOR and AC/ 
cAMP), as well as dopaminergic and GABAergic cell–cell
signaling processes (see Schwetye and Gutmann 2014). In
animal models, these Ras pathways are directly implicated
in attention, spatial learning and memory, and have led to
the development of novel pharmacological interventions for
ASD, ADHD, and learning problems within NF1. Together, 
this research suggests that NF1, as a rare genetic disorder,
should be prioritized to examine how Ras molecular path-
ways, and related dopaminergic and GABAergic signaling
pathways, contribute to risk for neurodevelopmental disor-
ders in the general population. Additionally, it highlights the
potential role of therapeutic targets related to Ras signaling,
which may generalize to a larger population. We will con-
clude by ofering future directions for NF1 research. 
Future research directions 
Focus on sample stratifcation methods 
Novel approaches to sample stratifcation may help to
reduce phenotypic and etiological heterogeneity and nar-
row in on specifc genetic pathways of risk. First, utiliz-
ing NF1 samples, or RASopathies samples more broadly,
will help to constrain the genetic risk architecture for
neurodevelopmental disorders on Ras pathways. Despite
allelic variation within NF1, this approach yields a more
genetically homogenous sample which may help to eluci-
date genetic variation that increases vulnerability for neu-
rodevelopmental disorders (O’Donovan and Owen 2016). 
Population birth cohorts and NF foundations (e.g., Chil-
dren’s Tumor Foundation), patient registries (Seidlin et al.
2017), and NF mutation repositories (e.g., Koczkowska
et al. 2019) may ofer access to patients and genetic and
phenotypic data for secondary analysis. 
Second, selecting neurodevelopmental disorder samples
from the general population based on an endophenotype
may improve identifcation of specifc genetic pathways
of risk. For example, macrocephaly is an easily measured
endophenotype, which may result from megalencephaly,
and is found at increased rates within ASD (Stevenson
et al. 1997) and NF1 (Van Es et al. 1996). Macrocephaly
may result, in part, from NF1 genetic variation that leads
to impaired apoptosis in neuronal cells during early devel-
opment (Pirozzi et al. 2018). A recent study conditioned
ASD on macrocephaly which led to the identifcation of
gene networks that are potentially disrupted and lead to
brain overgrowth (Schafer et  al. 2019), demonstrating
utility in this approach. Additionally, Klein et al. (2019) 
demonstrated an enhanced ability to detect ADHD suscep-
tibility loci by leveraging intracranial volume and other
measures of regional brain anatomy size. Pathway analy-
sis implicated genes involved in neurite outgrowth (Klein
et al. 2019), which is associated with NF1 via the Ras/Akt/ 
cAMP pathway (Anastasaki et al. 2015). 
Extend fndings from NF1 to examine common 
variation in Ras pathways 
Ras pathways implicated by NF1 may play an outsized
role in the development of ASD, ADHD, and SLD. The
genetic architecture of neurodevelopmental disorders con-
sists of both rare and common variation in Ras pathways;
however, it is possible that common and rare variation
implicate diferent biological processes. For example, the
types of genes identifed by rare and common variant stud-



























       
 
 
        
 






   
 
 














   






















(Boyle et al. 2017). However, emerging evidence indicates
that both rare and common variation within the Ras-ERK
pathway is enriched in ASD samples (Adviento et al. 2014; 
Pantaleoni et al. 2017; Pierpont and Wolford 2016; Vithay-
athil et al. 2018; Mitra et al. 2017). This convergence of
fndings suggests that the Ras-ERK pathway may provide
a therapeutic target for neurodevelopmental disorders for
individuals with or without a Rasopathy. 
Additionally, genome-wide association studies of ASD,
ADHD, and SLD may examine for enrichment of Ras path-
way genes. See Mitra et al. (2017) for a model on examin-
ing genetic variability for ASD in the general population
and RASopathies samples. Researchers interested in this
approach may consider utilizing the National Cancer Insti-
tute Ras Pathway 2.0 gene set which includes 227 genes
(McCormick 2015). Expression in the human brain for each
gene in this pathway was verifed with Allen Brain Atlas
(Hawrylycz et al. 2012) and GTEx Portal (Carithers and
Moore 2015) on 11/12/2019. Additionally, the use of protein
interaction bioinformatic tools such as STRING (Szklarc-
zyk et al. 2015) will further help to prioritize genes which
are functionally related to NF1. Combining bioinformatic
methods with functional enrichment approaches, like par-
titioned LD score regression (Finucane et al. 2015), will
allow researchers to examine if the NF1 related molecular
pathways are enriched in idiopathic neurodevelopmental
disorders. 
Finally, future genetic studies with NF1 samples may
leverage ADHD and ASD polygenic scores derived from
the general population (Alemany et al. 2019) to examine
the role of common neurodevelopmental susceptibility vari-
ants in contributing to risk in this population. If the genetic
architecture for neurodevelopmental disorders is similar both
within NF1 and outside of NF1, then drug-discoveries for
NF1 may more easily extend to the general population. 
Advancing from NF1 to molecular and cellular 
outcomes to guide treatment 
Functional studies involving NF1 animal and induced pluri-
potent stem cell (iPSC) NF1 patient derived neural cell mod-
els are needed to further detail the downstream efects of
variation in the NF1 gene. In particular, more studies involv-
ing functional modeling of the role of allelic variation in
NF1 and interaction of NF1 variants with diferent genetic
backgrounds are needed to understand phenotypic variability
within NF1 (see Wegscheid et al. 2018; Zhu et al. 2014). 
Such research may also shed light on the genetic architecture
of neurodevelopmental disorders in the general population,
especially if NF1 related pathways are implicated. 
NF1 animal models are critical for detailing molecular
and cellular pathways implicated in neurodevelopmental
disorders within this population. For example, Nf1 ± mice
demonstrated increased GABA, decreased long term
potentiation and decreased hippocampal dopamine which
was associated with learning difculties (Costa et al. 2002; 
Cui et al. 2008; Wegscheid et al. 2018). Such fndings
have led to the discovery of Lovastatin as a possible drug
to target attention and learning problems in the context
of NF1 (Li et  al. 2005). Lovastatin rescued long-term
potentiation and spatial learning defcits in Nf1 ± mice,
however, Lovastatin and Simvastatin trials in youth with
NF1 did not alter attention, intelligence, or visual spatial
learning (Payne et al. 2016; van der Vaart et al. 2013). 
One way to enhance the translations of efective interven-
tion from NF1 animal models to humans may be shift-
ing the therapeutic target. Due to the complex diferences
in behavioral measurement across species, interventions
which efectively target cross-species biomarkers related to
functional human outcomes should be prioritized (Acosta
2013; Sahin et al. 2018). For example, with resting-state
functional connectivity MRI, striatal dysfunction and dis-
rupted corticocortical connectivity in the default network
is evident across Nf1 ± mice and individuals with NF1
(Shofty et al. 2019). These neurodevelopmental outcomes
provide a similar therapeutic target across species. Indeed,
resting state fMRI measures were also improved in pilot
studies of Cogmed (Yoncheva et al. 2017) and Lovastatin
(Chabernaud et al. 2012). Additionally, using transcra-
nial magnetic stimulation, it was observed that lovasta-
tin decreased intracortical inhibition, increased synaptic
plasticity, and increased phasic alertness in adults with
NF1 (Mainberger et al. 2015). Thus, future research should
examine similarities in pathophysiology underlying neu-
rodevelopmental risk in NF1 animal models and humans. 
Human cell lines in NF1 allow the efects of allelic vari-
ation and genetic background on cellular phenotypes to be
investigated on a much larger scale (Wegscheid et al. 2018). 
For example, the use of multi-electrode arrays within iPSC
studies will allow for the neural cellular phenotypes within
NF1 to be examined (see Deneault et al. 2019 for example
in ASD). Additionally, cerebral organoids provide another
way to examine neurodevelopmental processes which are
disrupted in NF1 and may provide a model for more general
pathways to neurodevelopmental disorder risk. For exam-
ple, cerebral organoids derived from iPSCs from individu-
als with ASD show an accelerated cell-cycle and increased
GABAergic inhibitory neuron production, which is related
to increased FOXG1 expression (Mariani et al. 2015). FoxG1
also inhibits apoptosis, a process that is mediated by the
PI3K/Akt/mTOR pathway. Interestingly, fndings from idi-
opathic ASD-derived organoids (Mariani et al. 2015) are
consistent with increased Ras-ERK and Ras-mTOR activa-
tion within NF1 (see Fig. 1). Cellular or organoid pheno-
types within NF1 and other neurodevelopmental disorders































































heterogeneity in these populations, allowing for the identi-
fcation of more refned genetic architectures. 
Finally, our understanding of NF1 expression in brain tis-
sue is limited to animal models and iPSC cells. For example,
in a mouse model, the NF1 ex 9a isoform is associated with
learning, expressed exclusively in neurons, especially in the
cortex, hippocampus, striatum and septum during early post-
natal development (Gutmann et al. 1999). Similarly, mouse
models without NF1 ex23a show defcits in hippocampal
learning as well as motor delays; however, this isoform tends
to be more highly expressed in astrocytes (Costa et al. 2001).
Findings from these models need to be connected back to
the human brain. NF1 expression patterns in the developing
human brain can be examined through gene expression brain
atlases (e.g., Allen Brain Atlas). Such analyses will provide
a baseline for NF1 and related Ras pathway gene expres-
sion across time, region of the brain and cell type. Brain
organoids and assembloids also provide an opportunity to
examine expression of NF1 in human brain tissue. Incorpo-
rating CRISPR-Cas9 methods with these three-dimensional
cultures, allows for the ability to examine how NF1 allelic
variation efects cell structure and function. 
Conclusion 
NF1 provides a unique opportunity to investigate specifc
genetic pathways that contribute to the genetic architecture
underlying neurodevelopmental disorders in the general
population. The well-defned molecular pathways impli-
cated in neurodevelopmental disorders within NF1, such
as Ras/RAF/MEK/ERK, Akt/mTOR and AC/cAMP, may
inform the development of novel therapeutics, which ben-
eft a broader population. In sum, NF1 provides a model to
help us to better understand the etiological and phenotypic
heterogeneity within neurodevelopmental disorders, which
complements other methodological approaches focused on
refning genetic architecture. 
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